Communicated by Mireille Claustres
Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients†
Article first published online: 9 NOV 2007
© 2007 Wiley-Liss, Inc.
Volume 29, Issue 2, pages 258–266, February 2008
How to Cite
Guglieri, M., Magri, F., D'Angelo, M. G., Prelle, A., Morandi, L., Rodolico, C., Cagliani, R., Mora, M., Fortunato, F., Bordoni, A., Del Bo, R., Ghezzi, S., Pagliarani, S., Lucchiari, S., Salani, S., Zecca, C., Lamperti, C., Ronchi, D., Aguennouz, M., Ciscato, P., Di Blasi, C., Ruggieri, A., Moroni, I., Turconi, A., Toscano, A., Moggio, M., Bresolin, N. and Comi, G. P. (2008), Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum. Mutat., 29: 258–266. doi: 10.1002/humu.20642
- Issue published online: 14 JAN 2008
- Article first published online: 9 NOV 2007
- Manuscript Revised: 10 AUG 2007
- Manuscript Accepted: 10 AUG 2007
- Manuscript Received: 19 FEB 2007
- “Associazione Amici del Centro Dino Ferrari”; “Ricerca Finalizzata 2003, Ministero della Salute,” Italy
- Eurobiobank project. Grant Number: QLTR-2001-02769
- limb girdle muscular dystrophy;
Limb girdle muscular dystrophies (LGMD) are characterized by genetic and clinical heterogeneity: seven autosomal dominant and 12 autosomal recessive loci have so far been identified. Aims of this study were to evaluate the relative proportion of the different types of LGMD in 181 predominantly Italian LGMD patients (representing 155 independent families), to describe the clinical pattern of the different forms, and to identify possible correlations between genotype, phenotype, and protein expression levels, as prognostic factors. Based on protein data, the majority of probands (n=72) presented calpain-3 deficiency; other defects were as follows: dysferlin (n=31), sarcoglycans (n=32), α-dystroglycan (n=4), and caveolin-3 (n=2). Genetic analysis identified 111 different mutations, including 47 novel ones. LGMD relative frequency was as follows: LGMD1C (caveolin-3) 1.3%; LGMD2A (calpain-3) 28.4%; LGMD2B (dysferlin) 18.7%; LGMD2C (γ-sarcoglycan) 4.5%; LGMD2D (α-sarcoglycan) 8.4%; LGMD2E (β-sarcoglycan) 4.5%; LGMD2F (δ-sarcoglycan) 0.7%; LGMD2I (Fukutin-related protein) 6.4%; and undetermined 27.1%. Compared to Northern European populations, Italian patients are less likely to be affected with LGMD2I. The order of decreasing clinical severity was: sarcoglycanopathy, calpainopathy, dysferlinopathy, and caveolinopathy. LGMD2I patients showed both infantile noncongenital and mild late-onset presentations. Age at disease onset correlated with variability of genotype and protein levels in LGMD2B. Truncating mutations determined earlier onset than missense substitutions (20±5.1 years vs. 36.7±11.1 years; P=0.0037). Similarly, dysferlin absence was associated with an earlier onset when compared to partial deficiency (20.2±standard deviation [SD] 5.2 years vs. 28.4±SD 11.2 years; P=0.014). Hum Mutat 29(2), 258–266, 2008. © 2007 Wiley-Liss, Inc.